Furthermore, identification of individuals unlikely to respond to GLP-1 analogues early on would nullify the theoretical risk of exposing patients to a 6-month period of side-effects, ranging from nausea and vomiting to acute pancreatitis [14–17], and the significant expense associated with GLP-1 analogues without any clinical benefit [10]. The gene discussed is GCG; the disease is acute pancreatitis.